Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.

about

Hematopoietic stem cell transplantation for non-malignant gastrointestinal diseases

P2860

Q38291498-5F7506DC-0B1F-4FF7-9B87-4DC1AEBE968C

P2860

Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.

Item

http://www.wikidata.org/entity/Q38160461

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Increased mobilization and yie ...... lymphoma and multiple myeloma.

@en

type

Item

label

Increased mobilization and yie ...... lymphoma and multiple myeloma.

@en

prefLabel

Increased mobilization and yie ...... lymphoma and multiple myeloma.

@en

P1476

Increased mobilization and yie ...... lymphoma and multiple myeloma.

@en

P2093

Louis M Pelus

http://www.w3.org/2001/XMLSchema#string

Sherif S Farag

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data.

Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor.

Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.

Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment.

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.

Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.

Chemokine-mobilized adult stem cells; defining a better hematopoietic graft.

Management strategies for the hard-to-mobilize patient.

P304

11-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/SCCAA.S6713

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258337395

http://www.w3.org/2001/XMLSchema#string

P698

24198526

http://www.w3.org/2001/XMLSchema#string

P932

3781755

http://www.w3.org/2001/XMLSchema#string

Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.

about

P2860

P2860

Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932